Arvid Edén

Summary

Affiliation: Sahlgrenska University Hospital
Country: Sweden

Publications

  1. ncbi Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study
    Annica Lindkvist
    Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
    AIDS Res Ther 6:15. 2009
  2. ncbi Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients
    Arvid Edén
    Department of Infectious Diseases, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    AIDS Res Hum Retroviruses 26:533-40. 2010
  3. ncbi HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment
    Arvid Edén
    Department of Infectious Diseases, the Sahlgrenska Academy at University of Gothenburg, Sweden
    J Infect Dis 202:1819-25. 2010
  4. ncbi Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy
    Arvid Edén
    Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    J Infect Dis 196:1779-83. 2007
  5. ncbi Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
    Tomas Mellberg
    Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, Sweden
    AIDS Res Ther 8:21. 2011

Collaborators

Detail Information

Publications5

  1. ncbi Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study
    Annica Lindkvist
    Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
    AIDS Res Ther 6:15. 2009
    ..We propose that IVIG should be further evaluated as an adjuvant to effective ART...
  2. ncbi Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients
    Arvid Edén
    Department of Infectious Diseases, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    AIDS Res Hum Retroviruses 26:533-40. 2010
    ..EFV-based treatment gave a more rapid decline in HIV-1 RNA than did either of the boosted protease inhibitor-based regimens. The observed differences may reflect different inherent regimen potencies...
  3. ncbi HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment
    Arvid Edén
    Department of Infectious Diseases, the Sahlgrenska Academy at University of Gothenburg, Sweden
    J Infect Dis 202:1819-25. 2010
    ..We investigated CSF viral escape in subjects treated with commonly used antiretroviral therapy regimens in relation to intrathecal immune activation and central nervous system penetration effectiveness (CPE) rank...
  4. ncbi Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy
    Arvid Edén
    Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    J Infect Dis 196:1779-83. 2007
    ..5 years, a substantial proportion of patients continue to show signs of macrophage/microglia activation and intrathecal immunoglobulin production in the CNS...
  5. ncbi Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
    Tomas Mellberg
    Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, Sweden
    AIDS Res Ther 8:21. 2011
    ..abstract:..